Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV-1 | 11 | 2018 | 3365 | 1.65 | Why? |
| Substance Abuse, Intravenous | 7 | 2018 | 411 | 1.44 | Why? |
| Molecular Epidemiology | 8 | 2018 | 1638 | 1.12 | Why? |
| HIV Infections | 19 | 2019 | 11620 | 1.05 | Why? |
| Genotype | 11 | 2018 | 4697 | 0.98 | Why? |
| APOBEC Deaminases | 1 | 2021 | 58 | 0.87 | Why? |
| RNA Editing | 1 | 2021 | 80 | 0.85 | Why? |
| Adenosine Deaminase | 1 | 2021 | 85 | 0.83 | Why? |
| Drug Resistance, Viral | 5 | 2018 | 1083 | 0.75 | Why? |
| Drug Users | 2 | 2018 | 234 | 0.65 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.63 | Why? |
| Phylogeny | 14 | 2021 | 13341 | 0.60 | Why? |
| Recombination, Genetic | 3 | 2020 | 1265 | 0.60 | Why? |
| RNA Viruses | 1 | 2021 | 824 | 0.51 | Why? |
| RNA-Binding Proteins | 1 | 2021 | 1022 | 0.51 | Why? |
| Greece | 10 | 2021 | 2091 | 0.50 | Why? |
| Sequence Analysis, DNA | 5 | 2018 | 2830 | 0.46 | Why? |
| Social Networking | 1 | 2018 | 737 | 0.45 | Why? |
| Hepatitis B | 2 | 2018 | 888 | 0.43 | Why? |
| Hepatitis B virus | 1 | 2018 | 882 | 0.43 | Why? |
| Genome, Viral | 5 | 2021 | 13157 | 0.41 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.33 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.29 | Why? |
| Phylogeography | 2 | 2018 | 824 | 0.27 | Why? |
| Disease Transmission, Infectious | 4 | 2021 | 9044 | 0.25 | Why? |
| HIV | 4 | 2018 | 1116 | 0.25 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.24 | Why? |
| Epidemics | 4 | 2018 | 6407 | 0.23 | Why? |
| Cluster Analysis | 3 | 2018 | 3001 | 0.22 | Why? |
| Life Cycle Stages | 1 | 2021 | 162 | 0.21 | Why? |
| Embryonal Carcinoma Stem Cells | 1 | 2018 | 2 | 0.20 | Why? |
| ras Guanine Nucleotide Exchange Factors | 1 | 2018 | 3 | 0.20 | Why? |
| RNA, Double-Stranded | 1 | 2021 | 226 | 0.19 | Why? |
| Anti-HIV Agents | 3 | 2017 | 2209 | 0.19 | Why? |
| Asia, Central | 1 | 2018 | 18 | 0.19 | Why? |
| Pre-Exposure Prophylaxis | 2 | 2019 | 1138 | 0.19 | Why? |
| Genotyping Techniques | 2 | 2018 | 360 | 0.19 | Why? |
| Anti-Retroviral Agents | 2 | 2018 | 1099 | 0.18 | Why? |
| Opiate Alkaloids | 1 | 2017 | 7 | 0.18 | Why? |
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 30 | 0.18 | Why? |
| Endogenous Retroviruses | 1 | 2018 | 72 | 0.18 | Why? |
| Virus Integration | 1 | 2018 | 96 | 0.18 | Why? |
| HLA-B27 Antigen | 1 | 2018 | 48 | 0.18 | Why? |
| Adaptation, Biological | 1 | 2018 | 179 | 0.17 | Why? |
| DNA, Viral | 3 | 2018 | 2521 | 0.17 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 39 | 0.17 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 95 | 0.17 | Why? |
| Undocumented Immigrants | 1 | 2019 | 100 | 0.17 | Why? |
| Warfare | 1 | 2018 | 90 | 0.16 | Why? |
| Risk-Taking | 2 | 2018 | 508 | 0.16 | Why? |
| Mutation | 4 | 2021 | 12376 | 0.15 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2018 | 610 | 0.15 | Why? |
| Biological Evolution | 1 | 2021 | 641 | 0.15 | Why? |
| HIV Integrase Inhibitors | 1 | 2017 | 173 | 0.14 | Why? |
| Transgender Persons | 1 | 2019 | 322 | 0.14 | Why? |
| Minimally Invasive Surgical Procedures | 1 | 2020 | 663 | 0.14 | Why? |
| Weather | 1 | 2020 | 581 | 0.14 | Why? |
| Geography | 2 | 2018 | 1801 | 0.14 | Why? |
| Disease Outbreaks | 3 | 2017 | 27595 | 0.14 | Why? |
| Public Health Surveillance | 2 | 2018 | 3129 | 0.13 | Why? |
| Prevalence | 6 | 2018 | 25773 | 0.13 | Why? |
| Russia | 1 | 2018 | 989 | 0.13 | Why? |
| Sexual Behavior | 3 | 2018 | 1322 | 0.13 | Why? |
| Africa South of the Sahara | 1 | 2018 | 1335 | 0.13 | Why? |
| Social Stigma | 2 | 2019 | 1049 | 0.13 | Why? |
| Homosexuality, Male | 2 | 2019 | 1158 | 0.13 | Why? |
| Immunodominant Epitopes | 1 | 2018 | 813 | 0.12 | Why? |
| Harm Reduction | 1 | 2017 | 392 | 0.12 | Why? |
| Transcription, Genetic | 1 | 2018 | 1326 | 0.12 | Why? |
| Spatio-Temporal Analysis | 1 | 2018 | 1182 | 0.11 | Why? |
| Vaccination Coverage | 1 | 2021 | 1249 | 0.11 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 533 | 0.11 | Why? |
| Humans | 38 | 2021 | 930598 | 0.11 | Why? |
| Temperature | 1 | 2020 | 2305 | 0.11 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 3633 | 0.11 | Why? |
| Prisoners | 1 | 2019 | 738 | 0.10 | Why? |
| Ukraine | 2 | 2019 | 137 | 0.09 | Why? |
| Evolution, Molecular | 2 | 2021 | 3691 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 1 | 2018 | 1222 | 0.09 | Why? |
| Autoimmune Diseases | 1 | 2021 | 1996 | 0.08 | Why? |
| Genetic Variation | 1 | 2021 | 3919 | 0.08 | Why? |
| Chicago | 2 | 2019 | 653 | 0.08 | Why? |
| Genes, vpu | 1 | 2005 | 1 | 0.08 | Why? |
| Male | 19 | 2021 | 367725 | 0.08 | Why? |
| Genes, env | 1 | 2005 | 17 | 0.08 | Why? |
| Adult | 16 | 2021 | 244371 | 0.08 | Why? |
| Models, Statistical | 2 | 2021 | 5312 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2018 | 1666 | 0.08 | Why? |
| RNA, Viral | 3 | 2018 | 32276 | 0.07 | Why? |
| Health Promotion | 1 | 2019 | 2020 | 0.07 | Why? |
| Quality of Health Care | 1 | 2017 | 1948 | 0.07 | Why? |
| Health Status | 1 | 2019 | 3259 | 0.07 | Why? |
| Rheumatic Diseases | 1 | 2021 | 2675 | 0.07 | Why? |
| Social Support | 1 | 2019 | 3183 | 0.07 | Why? |
| Influenza Vaccines | 1 | 2021 | 2941 | 0.07 | Why? |
| Public Health | 2 | 2020 | 16359 | 0.07 | Why? |
| Europe | 2 | 2018 | 12702 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2019 | 3419 | 0.07 | Why? |
| Female | 17 | 2021 | 380317 | 0.06 | Why? |
| Simian Immunodeficiency Virus | 1 | 2005 | 251 | 0.06 | Why? |
| Substance-Related Disorders | 1 | 2017 | 2038 | 0.06 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.06 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.05 | Why? |
| Torque teno virus | 1 | 2001 | 73 | 0.05 | Why? |
| DNA Virus Infections | 1 | 2001 | 88 | 0.05 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.05 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.05 | Why? |
| Adolescent | 7 | 2021 | 86841 | 0.05 | Why? |
| Viral Load | 2 | 2018 | 15850 | 0.05 | Why? |
| Safe Sex | 1 | 2019 | 135 | 0.05 | Why? |
| Tumor Cells, Cultured | 1 | 2018 | 254 | 0.05 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.04 | Why? |
| Genes, MHC Class I | 1 | 2018 | 81 | 0.04 | Why? |
| Cyprus | 1 | 2018 | 186 | 0.04 | Why? |
| Fibronectins | 1 | 2018 | 92 | 0.04 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.04 | Why? |
| Raltegravir Potassium | 1 | 2017 | 132 | 0.04 | Why? |
| Delphi Technique | 1 | 2020 | 1257 | 0.04 | Why? |
| Aged | 8 | 2021 | 215776 | 0.04 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.04 | Why? |
| Geography, Medical | 1 | 2018 | 537 | 0.04 | Why? |
| Likelihood Functions | 1 | 2018 | 719 | 0.04 | Why? |
| Delayed-Action Preparations | 1 | 2017 | 291 | 0.04 | Why? |
| Genome, Human | 1 | 2018 | 400 | 0.04 | Why? |
| Drug Compounding | 1 | 2017 | 386 | 0.03 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2018 | 511 | 0.03 | Why? |
| Awareness | 1 | 2019 | 529 | 0.03 | Why? |
| Promoter Regions, Genetic | 1 | 2018 | 823 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.03 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2018 | 1517 | 0.03 | Why? |
| Mutation, Missense | 1 | 2018 | 863 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.03 | Why? |
| Global Health | 3 | 2020 | 13911 | 0.03 | Why? |
| Patient Compliance | 1 | 2021 | 1468 | 0.03 | Why? |
| United States | 1 | 2017 | 46150 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| DNA Primers | 2 | 2005 | 1170 | 0.02 | Why? |
| Sequence Alignment | 2 | 2005 | 2109 | 0.02 | Why? |
| Molecular Sequence Data | 2 | 2005 | 3198 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Cercopithecus | 1 | 2005 | 7 | 0.02 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Pan troglodytes | 1 | 2005 | 157 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Transcriptome | 1 | 2018 | 3466 | 0.02 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.02 | Why? |
| African Americans | 1 | 2019 | 3363 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.02 | Why? |
| Sequence Homology, Amino Acid | 1 | 2005 | 945 | 0.01 | Why? |
| Elective Surgical Procedures | 1 | 2020 | 5338 | 0.01 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.01 | Why? |
| Cloning, Molecular | 1 | 2005 | 1036 | 0.01 | Why? |
| Nucleic Acid Conformation | 1 | 2005 | 621 | 0.01 | Why? |
| Species Specificity | 1 | 2005 | 1356 | 0.01 | Why? |
| SARS Virus | 1 | 2004 | 13021 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Mass Screening | 1 | 2019 | 8005 | 0.01 | Why? |
| Polymerase Chain Reaction | 2 | 2005 | 6740 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Contact Tracing | 1 | 2018 | 8448 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Base Sequence | 1 | 2005 | 3581 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 8811 | 0.01 | Why? |
| Influenza, Human | 1 | 2021 | 10779 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Open Reading Frames | 1 | 2001 | 1898 | 0.01 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.01 | Why? |
| Amino Acid Sequence | 1 | 2005 | 6049 | 0.01 | Why? |
| Animals | 2 | 2017 | 78931 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2018 | 29620 | 0.01 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.01 | Why? |
| Viral Proteins | 1 | 2004 | 7370 | 0.00 | Why? |
Paraskevis's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(186)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(175)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_